JP2018512150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512150A5 JP2018512150A5 JP2017552992A JP2017552992A JP2018512150A5 JP 2018512150 A5 JP2018512150 A5 JP 2018512150A5 JP 2017552992 A JP2017552992 A JP 2017552992A JP 2017552992 A JP2017552992 A JP 2017552992A JP 2018512150 A5 JP2018512150 A5 JP 2018512150A5
- Authority
- JP
- Japan
- Prior art keywords
- oncolytic virus
- cancer
- virus
- pharmaceutical composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1505860.5 | 2015-04-07 | ||
| GBGB1505860.5A GB201505860D0 (en) | 2015-04-07 | 2015-04-07 | Therapeutic compositions and methods of use for treating cancer |
| PCT/GB2016/050973 WO2016162675A1 (en) | 2015-04-07 | 2016-04-07 | Therapeutic compositions and methods of use for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199987A Division JP7066812B2 (ja) | 2015-04-07 | 2020-12-02 | 癌を治療するための治療用組成物及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512150A JP2018512150A (ja) | 2018-05-17 |
| JP2018512150A5 true JP2018512150A5 (cg-RX-API-DMAC10.html) | 2019-05-16 |
Family
ID=53190234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552992A Pending JP2018512150A (ja) | 2015-04-07 | 2016-04-07 | 癌を治療するための治療用組成物及び使用方法 |
| JP2020199987A Active JP7066812B2 (ja) | 2015-04-07 | 2020-12-02 | 癌を治療するための治療用組成物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199987A Active JP7066812B2 (ja) | 2015-04-07 | 2020-12-02 | 癌を治療するための治療用組成物及び使用方法 |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN110856724B (zh) * | 2018-08-24 | 2022-05-27 | 杭州康万达医药科技有限公司 | 包含核酸及car修饰的免疫细胞的治疗剂及其应用 |
| EP3970754A4 (en) * | 2019-05-14 | 2023-08-02 | Oncolys BioPharma, Inc. | METHOD OF ADMINISTRATION OF ONCOLYTIC VIRUS TO TUMOR TISSUE AND DEVICE FOR ADMINISTRATION |
| CN115103905B (zh) * | 2020-01-10 | 2025-02-21 | 香港大学 | 表达α-1,3-半乳糖基转移酶的重组病毒及其用途 |
| PH12023551419A1 (en) * | 2020-11-30 | 2024-01-29 | Univ Cornell | Cancer immunotherapies to promote hyperacute rejection |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| WO2026068773A1 (en) * | 2024-09-27 | 2026-04-02 | Repudio Ab | Immunotherapy using ggta and nap |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9615794D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9810904D0 (en) | 1998-05-20 | 1998-07-22 | Univ London | Mutant herpes simplex viruses and uses thereof |
| JP4810042B2 (ja) | 2000-01-21 | 2011-11-09 | バイオヴェックス リミテッド | ヘルペスウイルス株 |
| US7338932B2 (en) * | 2000-05-11 | 2008-03-04 | Glycozym Aps | Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments |
| WO2002042468A2 (en) | 2000-11-27 | 2002-05-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030099616A1 (en) * | 2001-07-25 | 2003-05-29 | Irving John M. | Dual specificity tumor killing vectors driven by the telomerase promoter |
| AU2003285863A1 (en) * | 2002-10-09 | 2004-05-04 | Central Iowa Health System | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| US20050201993A1 (en) * | 2002-10-09 | 2005-09-15 | Link Charles J.Jr. | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| KR20070085314A (ko) * | 2004-11-12 | 2007-08-27 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 재조합 뉴캐슬 질환 바이러스 |
| US7820628B2 (en) | 2005-02-22 | 2010-10-26 | University Of Massachusetts Medical School | Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| EP2697368B1 (en) * | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| HK1210809A1 (en) * | 2012-12-07 | 2016-05-06 | 北卡罗来纳州大学 | Beta-hexosyl-transferases and uses thereof |
| CN105779397B (zh) * | 2014-12-22 | 2019-07-19 | 彭霞 | 溶瘤异源重组新城疫病毒及其制备方法与应用 |
-
2015
- 2015-04-07 GB GBGB1505860.5A patent/GB201505860D0/en not_active Ceased
-
2016
- 2016-04-07 KR KR1020177027601A patent/KR102544032B1/ko active Active
- 2016-04-07 MX MX2017012867A patent/MX377211B/es active IP Right Grant
- 2016-04-07 CA CA2981925A patent/CA2981925C/en active Active
- 2016-04-07 US US15/564,774 patent/US20180104288A1/en not_active Abandoned
- 2016-04-07 JP JP2017552992A patent/JP2018512150A/ja active Pending
- 2016-04-07 WO PCT/GB2016/050973 patent/WO2016162675A1/en not_active Ceased
- 2016-04-07 ES ES16716896T patent/ES2743952T3/es active Active
- 2016-04-07 EP EP16716896.2A patent/EP3280798B1/en active Active
- 2016-04-07 BR BR112017021700-7A patent/BR112017021700A2/pt not_active Application Discontinuation
- 2016-04-07 RU RU2017134519A patent/RU2720984C2/ru active
- 2016-04-07 HK HK18110254.0A patent/HK1251009B/en unknown
- 2016-04-07 CN CN201680020049.0A patent/CN107787364A/zh active Pending
-
2017
- 2017-10-02 IL IL254842A patent/IL254842B/en unknown
-
2019
- 2019-11-27 US US16/698,682 patent/US12023362B2/en active Active
-
2020
- 2020-12-02 JP JP2020199987A patent/JP7066812B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017134519A (ru) | Терапевтические композиции и способы применения для лечения рака | |
| JP6794442B2 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
| Everts et al. | Replication-selective oncolytic viruses in the treatment of cancer | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| ES2987444T3 (es) | Virus vaccinia recombinante y uso del mismo | |
| JP6576326B2 (ja) | 腫瘍溶解性アデノウイルス組成物 | |
| JP2007215547A (ja) | 変異体水疱性口内炎ウイルスおよびそれらの使用 | |
| RU2016146664A (ru) | Аденовирус, содержащий альбумин-связывающий участок | |
| JP2018519847A5 (cg-RX-API-DMAC10.html) | ||
| US10435672B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| Hastie et al. | An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells | |
| ES3014482T3 (en) | Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses | |
| JP7144915B2 (ja) | 腫瘍を治療するためのウイルス | |
| Li et al. | Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: The key to breaking the log jam? | |
| Bin Liu et al. | Virus, oncolytic virus and human prostate cancer | |
| WO2020011754A1 (en) | Chimeric vaccinia viruses | |
| JP7737141B2 (ja) | 細胞融合を誘導するワクシニアウイルス及びその利用 | |
| Liu et al. | Oncolytic vaccinia virotherapy for endometrial cancer | |
| Wu et al. | Viral delivery for gene therapy against cell movement in cancer | |
| JP2025188115A (ja) | 新規遺伝子組換えワクシニアウイルス及びその利用 | |
| Kemp et al. | Characterization of a replicating expanded tropism oncolytic reovirus carrying the adenovirus E4orf4 gene | |
| JP5964818B2 (ja) | 乳がんのウイルス療法用薬剤 | |
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| WO2018067165A1 (en) | Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer |